This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Gefitinib
From Proteopedia
(Difference between revisions)
(New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="Erlotinib/Erlotinib/1" align="right" caption="Erlotinib, also known as Tarceva"/> ===Better Known as: Iressa=== * Mark...) |
|||
| Line 1: | Line 1: | ||
| - | <applet load="" size="480" color="" frame="true" spin="on" Scene =" | + | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Gefitinib/Gefitinib/1" align="right" caption="Gefitinib, also known as Iressa"/> |
===Better Known as: Iressa=== | ===Better Known as: Iressa=== | ||
* Marketed By: AstraZeneca & Teva | * Marketed By: AstraZeneca & Teva | ||
* Major Indication: Pancreatic & Small Cel Lung [[Cancer]] | * Major Indication: Pancreatic & Small Cel Lung [[Cancer]] | ||
| - | * Drug Class: EGFR Inhibitor | + | * Drug Class: [[EGFR]] Inhibitor |
* Date of FDA Approval (Expiration): 2003 (2013) | * Date of FDA Approval (Expiration): 2003 (2013) | ||
* 2009 Sales: $268 Million | * 2009 Sales: $268 Million | ||
| Line 12: | Line 12: | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="6" align="center"| | + | ! colspan="6" align="center"| [[Epidermal Growth Factor Receptor]] Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID:16609030</ref><ref>PMID:17482782</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
Revision as of 13:01, 28 November 2010
|
Better Known as: Iressa
- Marketed By: AstraZeneca & Teva
- Major Indication: Pancreatic & Small Cel Lung Cancer
- Drug Class: EGFR Inhibitor
- Date of FDA Approval (Expiration): 2003 (2013)
- 2009 Sales: $268 Million
- Why You Should Care: It is the first selective inhibitor of Epidermal Growth Factor Receptors approved by the FDA
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Pharmacokinetics
| Epidermal Growth Factor Receptor Inhibitor Pharmacokinetics Comparison at Equivalent Dosages [1][2] | |||||
|---|---|---|---|---|---|
| Parameter | Erlotinib (Tarceva) | Gefitinib (Iressa) | |||
| Tmax (hr) | 2.0 | 5.4 | |||
| Cmax (ng/ml) | 69.6 | 130 | |||
| Bioavailability (%) | 99 | 59 | |||
| Protein Binding (%) | 93 | 90 | |||
| T1/2 (hr) | 9.4 | 26.9 | |||
| AUC (ng/ml/hr) | 20577 | 3850 | |||
| IC50 (nM) | 2 | 23 | |||
| Typical Dosage (mg) | 150 | 250 | |||
| Metabolism | Hepatic - (CYP3A4, CYP3A5, CYP2D6, CYP1A1) | Hepatic - (CYP3A4, CYP3A5, CYP2D6, CYP1A1, CYP1A2) | |||
References
- ↑ Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. PMID:16609030 doi:10.1158/1078-0432.CCR-05-2235
- ↑ Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, Swaisland H, Farmer MR, Cantarini MV, Lennernas H. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm. 2007 Aug 16;341(1-2):134-42. Epub 2007 Apr 6. PMID:17482782 doi:10.1016/j.ijpharm.2007.04.002
